Safety of IntraOperative Cell Salvage in visceral ONcologic surgery

Safety of IntraOperative Cell Salvage in visceral ONcologic surgery - SIOCSON

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033355

Enrollment

300

Registered

2024-01-05

Start date

2026-03-30

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

visceral cancer

Interventions

Group 1: Patients with visceral cancer surgery

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - written informed consent by the patient - elective visceral surgical tumor resection with suspected blood loss > 300 ml

Exclusion criteria

Exclusion criteria: - Infectious viral diseases (e.g. HBV, HCV, HIV, COVID-19)

Design outcomes

Primary

Measure	Time frame
Number of cancer cells in collected wound blood before and after cell salvage processing	—

Secondary

Measure	Time frame
- Number of cancer cells in patient blood before and after cancer surgery - Surface markers of CTCs, cancer cells from IOCS (intraoperative cell salvage) blood and the primarius - Functional properties of CTCs, cancer cells from IOCS blood and the primarius (e.g. viability, migration and invasion assays) - Gene expression of CTCs, tumor cells from IOCS blood and the main cancer	—

Countries

Germany

Contacts

Public ContactDania Fischer

Universitätsklinikum Heidelberg

dania.fischer@med.uni-heidelberg.de+496221-56-36166

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026